Karen Foster Sells 519 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 519 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $25.13, for a total transaction of $13,042.47. Following the sale, the insider directly owned 192,319 shares in the company, valued at $4,832,976.47. This represents a 0.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $25.34 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.62. The company has a 50 day moving average price of $26.30 and a 200 day moving average price of $24.52. The stock has a market capitalization of $1.22 billion, a P/E ratio of -361.95 and a beta of 1.93.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on BLFS shares. Wall Street Zen lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a report on Monday, November 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $31.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BLFS. T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioLife Solutions during the 1st quarter worth about $30,789,000. Royal Bank of Canada boosted its holdings in BioLife Solutions by 762.8% in the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock valued at $15,948,000 after purchasing an additional 617,320 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in BioLife Solutions by 2,399.5% in the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after purchasing an additional 238,533 shares in the last quarter. Summit Creek Advisors LLC purchased a new position in BioLife Solutions in the third quarter valued at approximately $4,905,000. Finally, Mutual of America Capital Management LLC increased its stake in BioLife Solutions by 22.2% in the second quarter. Mutual of America Capital Management LLC now owns 638,373 shares of the medical equipment provider’s stock valued at $13,751,000 after purchasing an additional 115,963 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.